Ubs Asset Management Americas Inc Recursion Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $417 Billion
- Q4 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 2,259,178 shares of RXRX stock, worth $23.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,259,178
Previous 2,140,750
5.53%
Holding current value
$23.4 Million
Previous $14.1 Million
8.26%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding RXRX
# of Institutions
339Shares Held
284MCall Options Held
2.83MPut Options Held
3.64M-
Vanguard Group Inc Valley Forge, PA34MShares$352 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl32.3MShares$335 Million1.91% of portfolio
-
Baillie Gifford & CO24.9MShares$257 Million0.13% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$179 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$152 Million0.44% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $1.87B
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...